MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI)

NCT02865616 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Clostridium Difficile Infection

Interventions

DRUG: MET-2
DRUG: Vancomycin

Sponsor

NuBiyota